SGMO Sangamo Therapeutics, Inc.
Healthcare$0.19+7.49%ClosedMarket Cap: $76.7M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-3.49
P/S
2.04
EV/EBITDA
-0.59
DCF Value
$-1.39
FCF Yield
-128.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-319.2%
Net Margin
-356.9%
ROE
6686.4%
ROA
-205.7%
ROIC
-1606.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $1.4M | 100.0% | $-31.9M | $-31.0M | $— | — |
| Q4 null | $14.2M | 100.0% | $-25.0M | $-37.4M | $— | — |
| FY null | $39.6M | 80.8% | $-108.0M | $-122.9M | $— | — |
| Q3 null | $581.0K | 100.0% | $-35.6M | $-34.9M | $— | — |
| Q2 null | $18.3M | 100.0% | $-17.9M | $-20.0M | $— | — |
| Q1 null | $6.4M | 100.0% | $-29.6M | $-30.6M | $— | — |
| Q4 null | $7.6M | 100.0% | $-26.0M | $-23.4M | $— | — |
| FY null | $57.8M | 100.0% | $-104.0M | $-97.9M | $— | — |
| Q3 null | $49.4M | 100.0% | $10.6M | $10.7M | $— | — |
| Q2 null | $356.0K | 100.0% | $-37.1M | $-36.1M | $— | — |
| Q1 null | $481.0K | 100.0% | $-51.5M | $-49.1M | $— | — |
| Q4 2023 | $2.0M | 100.0% | $-62.1M | $-60.3M | $-0.34 | — |